Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors

Sayadnejad, Nesa; Firouzjahi, Alireza; Shafaee, Shahryar; Golshahi, Hannaneh; Sokouti, Zahra; Gholinia, Hemmat; Ranaee, Mohammad

doi:10.5812/ijcm.5700

Cited by 6 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with Song et al, (2014), Shabbir et al, (2016) and Sayadnejad et al, (2017) we did not find a significant link between HER2 expression and tumor stage or lymph node metastasis (TN stage). On the contrary, Elwy et al, (2012) and Heppner et al, (2014) reported a significant association with higher stages and positive nodal status.…”

Section: Discussionsupporting

confidence: 93%

“…With respect to grade of differentiation in CRC cases, 4/6 of the positive and equivocal tumors were of low grade and exhibit mainly strong cytoplasmic/membranous expression, however no significant relationship was observed between CRC grades and HER2 pattern, which is consistent with several studies (Elwy et al, 2012;Pappas et al, 2013;Sayadnejad et al, 2017). However, several other studies reported the contrary.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Moussa

Badawy

Helal

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

with younger cases usually complicate polyposis and ulcerative colitis (El-Bolkainy et al., 2013). The outcome of CRC patients has significantly improved over the past decades, reflecting continuous progress in understanding its biology, epidemiology, prevention, early diagnosis and treatment (Siegel et al., 2017), but the identification of clinically actionable oncogenic drivers and related predicted biomarkers are largely elusive (Zhang et al., 2020). CRC is a tumor that develops from the progression of acquired or hereditary premalignant lesions. It arises from interactions among different risk factors (environmental,

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 86%

Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Moussa

Badawy

Helal

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…did not find any significant correlation between the stage of tumors and the expression of HER2/neu [35], but Shabbir et al find such a correlation [33].…”

Section:  Discussionmentioning

confidence: 92%

“…Along the time, there were controversies about the levels of HER2/neu overexpression in patients with CRC. There are articles showing strong positivity (range: 30-83%) in primary CRC, but also some others who found only 1.6% of their 1645 cases to be HER2/neu positive [33][34][35][36]. There are some studies reporting a worse prognosis for HER2/neu positive CRC patients [37,38].…”

Section:  Discussionmentioning

confidence: 99%

Clinical, histopathological and immunohistochemical features of brain metastases originating in colorectal cancer: a series of 27 consecutive cases

Scripcariu

Apostol

Dumitrescu³

et al. 2020

Rom J Morphol Embryol

View full text Add to dashboard Cite

Introduction: Brain metastases (BMs) originating in colorectal cancer (CRC) have a significant importance for patients' survival. Because in literature there are only isolated case reports and only few series published on this issue, we aimed to assess the incidence of BMs from CRC, to identify patient's characteristics and BMs clinical, histopathological (HP) and immunohistochemical (IHC) features, and to compare the data we obtained with those from literature. Patients, Materials and Methods: We present a retrospective study of 27 histologically confirmed cases of BMs from CRC among all 1040 patients who received metastasectomy in the Department of Neurosurgery, Prof. Dr. Nicolae Oblu Emergency Clinical Hospital, Iaşi, Romania, in an eight-year period (January 2011 to December 2018). Patients' characteristics (gender, age), primary tumor location, time from primary tumor surgery to BMs surgery and BMs features (number, location and HP characteristics) were investigated. Histochemical [Alcian Blue (AB) and Periodic Acid-Schiff (PAS)] staining and IHC stainings for cytokeratin (CK) 7, CK20, caudal-type homeobox 2 (CDX2) and human epidermal growth factor receptor 2 (HER2)/neu were performed on all available BMs specimens. Results: There were 27 consecutive patients with BMs from CRC, corresponding to 2.59% of all patients with BMs during the eight-year period we have studied, most of them being diagnosed and treated in 2016. Male:female ratio was 1.45. The mean age for all patients at diagnosis of the BMs was 62.25 years (range: 40-79 years). The origin of the primary cancer was mainly the colon (62.96% of all cases). Of all 27 patients, only two (7.4%) presented neurological symptoms without a diagnosis of CRC. BMs were identified in a period ranging from six months to 70 months after the initial diagnosis. The average time between diagnosis of the primary tumor and of the BMs was 25.92 months. At the moment of the diagnosis of BMs, 17 (62.96%) patients also had other systemic metastases. Most of the cases (55.55%) were situated in the supratentorial compartment. IHC stainings were negative for CK7 and positive for CK20 and CDX2 in all BMs from colonic adenocarcinomas (ADCs), a profile consistent with a non-neuronal and gastric origin. AB and PAS stainings revealed pools of extracellular mucin, especially in cases of mucinous ADC. Ki67 labeling index ranged between 90% and 100%. IHC staining with anti-HER2/neu antibody showed in 25 (96.15%) cases a strong and diffuse aberrant nuclear staining. Conclusions: BMs originating in CRC represent a rare pathology and have particular clinical and IHC features that could vary from one series to another series. In a few cases, BMs may be diagnosed in the absence of a known CRC diagnosis and in these situations, the correct diagnosis is of interest. However, a panel of antibodies can help in establishing a correct diagnosis. Our study was among the first to analyze the HER2/neu expression pattern in BMs from CRC and we found a strong aberrant nuclear expression of this molec...

show abstract

“…University 2020;7(3 (11). Benzer şekilde Sayadnejad ve arkadaşları 50 olguluk çalışmalarında, yaş, tümör boyutu, cinsiyet, lokasyon, derece ve evre ile HER-2/neu ekspresyonu arasında anlamlı ilişki saptamamışlardır (13). Priyanka ve arkadaşları ise çalışmalarına dahil ettikleri 25 kolorektal kanserli olgunun tamamında HER-2/neu ekspresyonunu negatif saptamışlardır (14).…”

Section: Discussionunclassified

Kolorektal Kanserlerde HER-2/neu Ekspresyonunun Histopatolojik ve Prognostik Parametrelerle Korelasyonu

Celi̇k

Tekin

2020

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi

View full text Add to dashboard Cite

Kolorektal kanser gastrointestinal kanserlerin en sık görülen tipidir, kadınlarda ikinci, erkeklerde üçüncü en yaygın görülen kanserdir ve kansere bağlı ölüm nedenleri arasında 3. sıradadır. Prognoz birçok klinik ve patolojik parametre ile ilişkili olsa da en önemli faktör TNM sınıflamasına göre olan evresidir. Ancak aynı patolojik evrede olmasına rağmen prognozlar arasında farklılıklar da bulunmaktadır. Bu durum TNM evresi dışında yeni prognostik ve prediktif faktörlere olan ihtiyacı ortaya koymaktadır. C-erbB-2 olarak da bilinen, tirozin kinaz aktivitesi ile bir transmembran proteini kodlayan gen olan HER-2/neu, epidermal büyüme faktörü ile biyolojik olarak yakından ilişkili bir protoonkogendir. HER2/neu'nun aşırı ekspresyonu akciğer, prostat, mesane, pankreas ve meme gibi birçok epitelyal malignitelerde tespit edilmiştir. Bu çalışmanın amacı; kolorektal kanserlerde HER-2/neu onkogeni ekspresyonunu immunohistokimyasal yöntemlerle belirlemek, aşırı ekspresyonu ile çeşitli prognostik faktörler arasındaki ilişkiyi incelemektir. Çalışmamızda 2013-2020 tarihleri arasında hastanemizde kolorektal kanser tanısı alan 111 olguya ait rezeksiyon materyallerinden seçilen tümörlü bloklardan Leica Bond-Max cihazında, anti-C-erbB-2 antikoru(Leica) kullanılarak otomatik sistemle immunohistokimyasal boyama yapıldı. HER-2/neu'nun aşırı ekspresyonu patolojik evre, tümör diferansiasyonu, lenfovasküler invazyon, perinöral invazyon, çevre(radial) cerrahi sınır pozitifliği, lenf nodu tutulumu ve uzak metastaz varlığı ile anlamlı derecede ilişkili olduğu saptandı. Bu sonuçlar, kolorektal kanserli hastalarda HER-2/neu ekspresyonunun tespitinin, hastalığın prognozunu öngörmede ve tedavi protokollerinin belirlenmesinde yol gösterici olabileceğini düşündürmektedir.

show abstract

Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors

Cited by 6 publications

References 43 publications

Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Clinical, histopathological and immunohistochemical features of brain metastases originating in colorectal cancer: a series of 27 consecutive cases

Kolorektal Kanserlerde HER-2/neu Ekspresyonunun Histopatolojik ve Prognostik Parametrelerle Korelasyonu

Contact Info

Product

Resources

About